Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 12, 2007 - Issue 3
Submit an article Journal homepage
88
Views
18
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for non-small-cell lung cancer

Enriqueta Felip Institut Català d'Oncologia, Hospital Germans Trias I Pujol, Ctra. Canyet. s/n, 08916 Badalona, Barcelona, Spain +34 93 497 8925+34 93 497 8950; [email protected]
,
Mariacarmela Santarpia Institut Català d'Oncologia, Hospital Germans Trias I Pujol, Ctra. Canyet. s/n, 08916 Badalona, Barcelona, Spain +34 93 497 8925+34 93 497 8950; [email protected]
&
Rafael Rosell Institut Català d'Oncologia, Hospital Germans Trias I Pujol, Ctra. Canyet. s/n, 08916 Badalona, Barcelona, Spain +34 93 497 8925+34 93 497 8950; [email protected]
Pages 449-460 | Published online: 17 Sep 2007

Bibliography

  • SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. (2002) 346:92-98.
  • SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. (2000) 18:2095-2103.
  • HANNA N, SHEPHERD FA, FOSSELLA FV et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. (2004) 22:1589-1597.
  • SANDLER A, GRAY R, PERRY MC et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. (2006) 355:2542-2550.
  • SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.; National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353:123-132.
  • OZOLS RF, HERBST RS, COLSON YL et al.: Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American society of clinical oncology. J. Clin. Oncol. (2007) 25:146-162.
  • IMAI K, TAKOAKA A: Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer (2006) 6:714-727.
  • BILD AH, POTTI A, NEVINS JR: Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer (2006) 6:735-741.
  • MAIONE P, GRIDELLI C, TROIANI T, CIARDELLO F: Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist (2006) 11:274-284.
  • NATALE RB, BODKIN D, GOVIDAN R et al.: ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized Phase II trial. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7000.
  • HEYMACH JV, JOHNSON BE, PRAGER D et al.: A Phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7016.
  • MORABITO A, DE MAIO E, DI MAIO M et al.: Tyrosine kinase inhibitors of vacular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist (2006) 11:753-764.
  • LAURIE SA, ARNOLD A, GAUTHIER I et al.: Final results of a Phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24 No. S18 (20 Suppl.) (2006):3054.
  • VAN CRUIJSEN, VOEST EE, VAN HERPEN CM et al.: Phase I clinical evaluation of AZD2171 in combination with gefitinib in patients with advanced tumors. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings. 23:S199.
  • GRIDELLI C, MAIONE P, DEL GAIZO F et al.: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist (2007) 12:191-200.
  • GATZEMEIER U, BLUMENSCHEIN G, FOSSELLA F et al.: Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7002.
  • SCHILLER JH, FLAHERTY KT, REDLINGER M et al.: Sorafenib combined with carboplatin/paclitxel for advanced non-small cell lung cancer: a phase I subset analysis. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7194.
  • CHOW LQM, ECKHARDT SG: Sunitinib: From rational design to clinical efficacy. J. Clin. Oncol. (2007) 25:884-896.
  • SOCINSKI MA, NOVELLO S, SANCHEZ JM et al.: Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter Phase II trial. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7001.
  • GIACCONE G: The potential of antiangiogenic therapy in non-small cell lung cancer. Clin. Cancer Res. (2007) 13:1961-1970.
  • PUJOL JL, BRETON JL, GERVAIS R et al.: A prospective randomized Phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): an intergroup study FNCLCC Cleo04-IFT 00-01. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7057.
  • DOWLATI A, SUBBIAH S, COONEY M et al.: Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer (2007) [Epub ahead of print].
  • HEYMACH JV, NILSSON M, BLUMENSCHEIN G et al.: Epidermal growth factor receptor inhibitors in development for the treatment of non-small-cell lung cancer. Clin. Cancer Res. (2006) 12(14 Suppl):S4441-S4445.
  • LILENBAUM RC: The evolving role of cetuximab in non-small cell lung cancer. Clin. Cancer Res. (2006) 12(14 Suppl):S4432-S4435.
  • HANNA N, LILENBAUM R, ANSARI R et al.: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol. (2006) 24:5253-5258.
  • THIENELT CD, BUNN PA, HANNA N et al.: Multicenter Phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:8786-8793.
  • ROBERT F, BLUMENSCHEIN G, HERBST RS et al.: Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:9089-9096.
  • ROSELL R, DANIEL C, RAMLAU R et al.: Randomized Phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) expressing advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 2004 ASCO Annual Meeting Proceedings. Volume 22, No. S14 (15 Suppl.) (2004):7012.
  • KELLY K, HERBST RS, CROWLEY JJ et al.: Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small-cell lung cancer (NSCLC): a randomized Phase II selectional trial SWOG 0342. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7015.
  • MUKOAHARA T, ENGELMAN JA, HANNA N et al.: Differential effects of gefitinib and cetuximab on non-small cell lung cancer bearing epidermal growth factor mutations. J. Natl. Cancer Inst. (2005) 97:1185-1194.
  • PEREZ-TORRES M, GUIX M, GONZALEZ A, ARTEAGA CL: Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptor and inhibits tumors expressing EGFR mutations. J. Biol. Chem. (2006) 281:40183-40192.
  • STEINER P, JOYNES C, BASSI R et al.: Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin. Cancer Res. (2007) 13:1540-1551.
  • KOLLMANNSBERGER C, SCHITTENHELM M, HONECKER F et al.: A Phase I study of the humanized monoclonal anti-epidermal growth factor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC). Ann. Oncol. (2006) 17:1007-1013.
  • RUSNAK DW, LACKEY K, AFFLECK K et al.: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. (2001) 1:85-94.
  • XIA W, MULLIN RJ, KEITH BR et al.: Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21:6255-6263.
  • BURRIS HA, HURWITZ HI, DEES EC et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. (2005) 23:5305-5313.
  • RAVAUD A, GARDNER J, HAWKINS R et al.: Efficacy of lapatinib in patients with high tumor EGFR expression: results of a Phase III trial in advanced renal cell carcinoma (RCC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):4502.
  • ROSS HJ, BLUMENSCHEIN GR, DOWLATI A et al.: Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings. Part I. Volume 23, No. S18:7099.
  • RABINDRAN SK, DISCAFANI CM, ROSFJORD EC et al.: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. (2004) 64:3958-3965.
  • KWAK EL, SORDELLA R, BELL DW et al.: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA (2005) 102:7665-7670.
  • WONG KK, FRACASSO PM, BUKOWSKI RM et al.: HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary Phase I results in patients with solid tumors. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):3018.
  • SHIMAMURA T, JI H, MINAMI Y et al.: Non-small cell lung cancer and Ba/F3 transformed cells harbouring the ERBB2 G776V_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. (2006) 66:6487-6491.
  • MINAMI Y, SHIMAMURA T, SHAH K et al.: The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene (2007) [Epub ahead of print].
  • JI H, ZHAO X, YUZA Y et al.: Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. USA (2006) 103:7817-7822.
  • WISSNER A, OVERBEEK E, REICH MF et al.: Synthesis and structure-activity relationship of 6,7-disubstituted 4-aniloquinilone-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. (2003) 46:49-63.
  • TORRANCE CJ, JACKSON PE, MONTGOMERY E et al.: Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. (2000) 6:1024-1028.
  • ERLICHMAN C, HIDALGO M, BONI JO et al.: Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. (2006) 24:2252-2260.
  • YOSHIMURA N, KUDOH S, KIMURA T et al.: EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, withclinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer (2006) 51:363-368.
  • SáNCHEZ JM, MELLEMGAARD A, PERRY M et al.: Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): a Phase I/II trial. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7104.
  • VANSTEENKISTE J, LARA PN, LE CHEVALIER T et al.: Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J. Clin. Oncol. (2007) [Epub ahead of print].
  • STINCHCOMBE TE, SOCINSKI MA, WALKO CM et al.: Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors. Cancer Chemother. Pharmacol. (2007) [Epub ahead of print].
  • GREEN MR, MANIKHAS GM, ORLOV S et al.: Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. (2006) 17:1263-1268.
  • RIZVI NA, AZZOLI C, MILLER V et al.: Phase I/II study of ABI-007 as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7105.
  • RICHARDS DA, RICHARDS P, BODKIN D et al.: Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients with advanced-stage non-small-cell lung cancer: results of a Phase II study. Clin. Lung Cancer (2005) 7:215-220.
  • BODDY AV, PLUMMER ER, TODD R et al.: A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. (2005) 11:7834-7840.
  • ROSS H, BONOMI P, LANGER C et al.: Effect of gender on outcome in two randomized Phase III trials of paclitaxel poliglumex (PPX) in chemonaïve patients with advanced NSCLC and poor performance status (PS2). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7039.
  • BONOMI P, LANGER C, O'BRIEN M et al.: Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: cox regression analysis of randomized Phase III trial comparing docetaxel and paclitaxel poliglumex (PPX). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7040.
  • BENNOUNA J, BRETON JL, TOURANI JM et al.: Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a Phase II study. Br. J. Cancer (2006) 94:1383-1388.
  • KZRAKOWSKI M, DOUILLARD J, RAMLAU R et al.: Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimens. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings. Part I. Volume 25, No. S18 (20 Suppl.) (2007):7511.
  • FANUCCHI MP, FOSELLA FV, BELT R et al.: Randomized Phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. (2006) 24:5025-5033.
  • DAVIES AM, MCCOY J, LARA PM et al.: Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results encouraging survival in advanced non-small cell lung cancer (NSCLC): results of a Phase II Southwest Oncology Group (SWOG) trial (S0339). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):7017.
  • BLOBE GC, OBEID LM, HANNUN YA: Regulation of protein kinase c and role in cancer biology. Cancer Metast. Rev. (1994) 13:411-431.
  • GRAFF JR, MCNULTY AM, HANNA KR et al.: The protein kinase C β-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. (2005) 65:7462-7469.
  • HANAUSKE AR, OBERSCHMIDT O, HANAUSKE-ABEL H et al.: Antitumor activity of enzastaurin (LY317615.HCI) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments. Investig. New Drugs (2007) [Epub ahead of print].
  • CARDUCCI MA, MUSIB L, KIES MS, et al.: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol. (2006) 24:4092-4099.
  • FINE HA, KIM L, ROYCE C et al.: Results from Phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings. Volume 23, No. S16:1504.
  • DUDKIN L, DILLING MB, CHESHIRE PJ et al.: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. (2001) 7:1758-1764.
  • NESHAT MS, MELLINGHOFF IK, TRAN C et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA (2001) 98:10314-10319.
  • HIDALGO M, BUCKNER JC, ERLICHMAN C et al.: A Phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced camcer. Clin. Cancer Res. (2006) 12:5755-5763.
  • CHAN S, SCHEULEN ME, JOHNSTON S et al.: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, inheavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. (2005) 23:5314-5322.
  • GALANIS E, BUCKNER JC, MAURER MJ et al.: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. (2005) 23:5294-5304.
  • WITZIG TE, GEYER SM, GHOBRIAL I et al.: Phase II trial of single-agent temsirolimus (CCI-779) for relapses mantle cell-lymphoma. J. Clin. Oncol. (2005) 5347-5356.
  • GOUDAR RK, SHI Q, HJELMELAND MD et al.: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer. Ther. (2005) 4:101-112.
  • DRUMMOND DC, NOBLE CO, KIRPOTIN DB et al.: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. (2005) 45:495-528.
  • DOKMANOVIC M, MARKS PAUL A: Prospects: histone deacetylase inhibitors. J. Cell. Biochem. (2005) 96:293-304.
  • KOMATSU N, KAWAMATA N, TAKEUCHI S et al.: SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol. Rep. (2006) 15:187-191.
  • MARKS PA: Discovery and development of SAHA as anticancer agent. Oncogene (2007) 26:1351-1356.
  • KELLY WK, RICHON VM, O'CONNOR O et al.: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. (2003) 9:3578-3588.
  • KELLY WK, O'CONNOR OA, KRUG LM et al.: Phase I study of an oral histone deacetylase inhibitor, Suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. (2005) 23:3923-3931.
  • RAMALINGAM S, PARISE RA, EGORIN MJ et al.: Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin and paclitaxel for patients with advanced solid malignancies. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. S18 (20 Suppl.) (2006):2077.
  • OLSEN EO, KIM Y,KUZEL T et al.: Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): results of a Phase IIb trial. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings. Part I. Volume 24, No. 18S (20 Suppl.) (2006):7500.
  • HERBST RS, JOHNSON DH, MININBERG E et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:2544-2555.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.